DDInter462 DDInter1676
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dabrafenib {u} (Compound) binds {v} (Gene) SLCO1B3
Dabrafenib {u} (Compound) upregulates {v} (Gene) PSAT1
Dabrafenib {u} (Compound) is included by {v} (Pharmacologic Class) Organic Anion Transporter 3 Inhibitors
Dabrafenib {u} (Compound) downregulates {v} (Gene) LIG1
Dabrafenib {u} (Compound) causes {v} (Side Effect) Abdominal pain
Dabrafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Dabrafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Levacetylmethadol
Dabrafenib (Compound) binds SLCO1B3 (Gene)
Dabrafenib (Compound) upregulates PSAT1 (Gene)
Dabrafenib (Compound) is included by Organic Anion Transporter 3 Inhibitors (Pharmacologic Class)
Dabrafenib (Compound) downregulates LIG1 (Gene)
Dabrafenib (Compound) causes Abdominal pain (Side Effect)
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Dabrafenib may lead to a major life threatening interaction when taken with Levacetylmethadol